Changes in viral hepatitis B screening practices over time in West African HIV clinics.

Coffie, P A; Patassi, A; Doumbia, A; Bado, G; Messou, E; Minga, A; Allah-Kouadio, E; Zannou, D M; Seydi, M; Kakou, A R; Dabis, F; Wandeler, Gilles (2017). Changes in viral hepatitis B screening practices over time in West African HIV clinics. Médecine et maladies infectieuses, 47(6), pp. 394-400. Elsevier Masson 10.1016/j.medmal.2017.04.011

Preview	Text Coffie MedMalInfect 2017_postprint.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (153kB) | Preview
	Text Coffie MedMalInfect 2017.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (567kB)

BACKGROUND

We aimed to describe changes in hepatitis B screening practices over a 3-year period among HIV-infected patients in West Africa.

METHODS

A medical chart review was conducted in urban HIV treatment centers in Ivory Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who started antiretroviral treatment between 2010 and 2012, 100 per year were randomly selected from each clinic. Demographic, clinical, and laboratory data was collected using a standardized questionnaire. We assessed changes in the proportion of patients screened over time and identified predictors of screening in a multivariable logistic regression.

RESULTS

A total of 2097 patients were included (median age: 37 years, 65.4% of women). Overall, 313 (14.9%) patients had been screened for hepatitis B, with an increase from 10.6% in 2010 to 18.9% in 2012 (P<0.001) and substantial differences across countries. In multivariable analysis, being aged over 45 years (adjusted odds ratio: 1.34 [1.01-1.77]) and having an income-generating activity (adjusted odds ratio: 1.82 [1.09-3.03]) were associated with screening for hepatitis B infection. Overall, 62 HIV-infected patients (19.8%, 95% confidence interval: 15.5-24.7) were HBsAg-positive and 82.3% of them received a tenofovir-containing drug regimen.

CONCLUSION

Hepatitis B screening among HIV-infected patients was low between 2010 and 2012. The increasing availability of HBsAg rapid tests and tenofovir in first-line antiretroviral regimen should improve the rates of hepatitis B screening.

Interest & Impact

Downloads

405 since deposited on 04 Jul 2017
55 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item